Lung Cancer
Conference Coverage
Durvalumab pre, post surgery in NSCLC: Practice changing?
A new study’s findings confirm the benefits of neoadjuvant immunotherapy.
Latest News
Cancer, heart disease vaccines may be ready by 2030, Moderna says
The announcement is yet another sign of what many are calling “the golden age” of vaccine development.
News
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
Conference Coverage
Study gives new insight into timing of combo treatment in metastatic NSCLC
Best outcomes came when immunotherapy followed radiotherapy by 1-12 months.
Conference Coverage
First target doesn’t affect survival in NSCLC with brain metastases
Patient outcomes didn’t hinge on whether oncologists treated the brain or lung first.
Conference Coverage
Type of insurance linked to length of survival after lung surgery
Having public or a combination of public and private insurance was associated with worse 10-year overall survival.
News
Thoracic cancer approvals differ at FDA, EMA
The EMA had fewer approvals and took longer to make decisions.
Conference Coverage
In metastatic NSCLC, better QoL outcomes tied to better outcomes
But the authors of new research also found potential evidence that industry sponsorship may lead to a spin on QoL outcomes.
News
SBRT: Alternative to surgery in early stage lung cancer?
“From a public health perspective, SBRT is a good therapeutic option in terms of survival, especially for elderly and inoperable patients.”
News
Low-dose olanzapine improves appetite in chemotherapy patients
About half of patients who took olanzapine consumed more than 75% of recommended daily calories.
